ArticleExperimental and therapeutic medicine2026
No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-peptidic thrombopoietin receptor agonists (TPO-RAs), including eltrombopag, avatrombopag and hetrombopag, are used as second-line therapies for immune thrombocytopenia (ITP). However, concerns regarding their hepatic safety persist. The present study conducted a meta-analysis by searching PubMed, Web of Science and the Chinese Medical Association Journal Database for randomized controlled trials evaluating non-peptidic TPO-RAs in ITP that reported hepatic enzyme outcomes, specifically alanine aminotransferase and/or aspartate aminotransferase. The present meta-analysis therefore assessed data from 13 randomized controlled trials involving 1,480 patients (1,034 in the intervention arm and 446 in the control arm) to evaluate the risk of hepatic enzyme abnormalities associated with these aforementioned agents. The results revealed that non-peptidic TPO-RAs did not significantly increase the incidence of hepatic enzyme elevation events in the intervention group compared with that in the control group [odds ratio (OR)=1.30; 95% CI, 0.82-2.07; P=0.27]. The risk of hepatic enzyme elevation events in patients receiving TPO-RAs remained non-significant when analyses were restricted to studies with a treatment duration of ≥6 weeks (OR=1.28; 95% CI: 0.78-2.08; P=0.33), to studies that exclusively enrolled adults (OR=1.24; 95% CI, 0.77-1.99; P=0.37, and to studies reporting severe transaminase elevations defined as ≥3 times the upper limit of that considered normal (OR=1.66; 95% CI, 0.59-4.65; P=0.34). Subgroup analyses also showed no significant increase in hepatic enzyme elevation events with eltrombopag (OR=1.68; 95% CI, 0.93-3.04; P=0.09), avatrombopag (OR=0.88; 95% CI, 0.09-8.46; P=0.91) or hetrombopag (OR=1.04; 95% CI, 0.30-3.65; P=0.95). These findings suggest that non-peptidic TPO-RAs did not significantly increase the incidence of hepatic enzyme elevation events in patients with ITP compared with that in controls and support their continued clinical use with appropriate liver function monitoring. The present meta-analysis was registered in the International Prospective Register of Systematic Reviews (registration no. CRD420251084782).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.